Samjin Pharm (005500) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Samjin Pharm (005500) has a cash flow conversion efficiency ratio of -0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.43 Billion ≈ $-969.50K USD) by net assets (₩264.51 Billion ≈ $179.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Samjin Pharm worth for the company's overall valuation and market capitalisation.
Samjin Pharm - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Samjin Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Samjin Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Samjin Pharm ranked by their cash flow conversion efficiency. Explore cash flow quality index of Samjin Pharm to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rugvista Group AB
ST:RUG
|
0.006x |
|
BriQ Properties Real Estate Investment Company
AT:BRIQ
|
0.005x |
|
TONT
NYSE MKT:TONT
|
0.000x |
|
First Steamship Co Ltd
TW:2601
|
0.018x |
|
Seoho Electric Co.Ltd
KQ:065710
|
0.039x |
|
DCW Limited
NSE:DCW
|
0.121x |
|
AFC Ajax NV
AS:AJAX
|
0.032x |
|
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
NASDAQ:ZJYL
|
-0.031x |
Annual Cash Flow Conversion Efficiency for Samjin Pharm (2013–2024)
The table below shows the annual cash flow conversion efficiency of Samjin Pharm from 2013 to 2024. View current stock price of Samjin Pharm for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩261.66 Billion ≈ $177.32 Million |
₩38.15 Billion ≈ $25.86 Million |
0.146x | +364.31% |
| 2023-12-31 | ₩265.36 Billion ≈ $179.83 Million |
₩8.33 Billion ≈ $5.65 Million |
0.031x | -49.90% |
| 2022-12-31 | ₩275.86 Billion ≈ $186.95 Million |
₩17.29 Billion ≈ $11.72 Million |
0.063x | -38.75% |
| 2021-12-31 | ₩234.17 Billion ≈ $158.69 Million |
₩23.97 Billion ≈ $16.24 Million |
0.102x | -8.44% |
| 2020-12-31 | ₩213.46 Billion ≈ $144.66 Million |
₩23.86 Billion ≈ $16.17 Million |
0.112x | -6.60% |
| 2019-12-31 | ₩197.47 Billion ≈ $133.83 Million |
₩23.63 Billion ≈ $16.02 Million |
0.120x | -18.32% |
| 2018-12-31 | ₩205.32 Billion ≈ $139.14 Million |
₩30.08 Billion ≈ $20.39 Million |
0.147x | -23.97% |
| 2017-12-31 | ₩193.47 Billion ≈ $131.11 Million |
₩37.28 Billion ≈ $25.27 Million |
0.193x | -32.79% |
| 2016-12-31 | ₩169.69 Billion ≈ $115.00 Million |
₩48.66 Billion ≈ $32.97 Million |
0.287x | +124.21% |
| 2015-12-31 | ₩148.06 Billion ≈ $100.34 Million |
₩18.94 Billion ≈ $12.83 Million |
0.128x | -50.26% |
| 2014-12-31 | ₩126.04 Billion ≈ $85.42 Million |
₩32.41 Billion ≈ $21.96 Million |
0.257x | +293.92% |
| 2013-12-31 | ₩112.98 Billion ≈ $76.57 Million |
₩7.37 Billion ≈ $5.00 Million |
0.065x | -- |
About Samjin Pharm
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also… Read more